ImmuNext
Business Services · New Hampshire, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Medical Center Dr, Lebanon, New Hampsh...Phone Number
(802) 649-8109Website
www.immunext.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ImmuNext
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Novel immunomodulators have been partnered with Janssen, Roche and Sanofi. ImmuNext currently has a clinical stage program with VISTA, a checkpoint regulator, and pre-clinical programs focused on the development of antibodies that target novel immuno-metabolic proteins.Explore more
ImmuNext Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ImmuNext your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
ImmuNext, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if ImmuNext had a recent Job posting/layoffs
Earning: See what the market has to say on ImmuNext recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at ImmuNext
Website visits: Recent activity has been detected on your website
Check if ImmuNext has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when ImmuNext launches new products
Check out if ImmuNext is spiking on competitors!
Funding: Get notified immidiatlly once ImmuNext has new funding data
Recommended Actions
Reach out to Masked Content who joined ImmuNext as Masked Content
Find 2 more new buyers
Compare Similar Companies to ImmuNext
Compare insights from companies similar to ImmuNext, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ImmuNext is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ImmuNext is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ImmuNext.
ImmuNext Tech Stack
A closer look at the technologies used by ImmuNext
ImmuNext News & Media
Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies
LEXINGTON, Mass., Jan. 7, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an option and license agreement to acquire exclusive, worldwide...Lilly and ImmuNext Announce Licensing and Research Collaboration
INDIANAPOLIS and LEBANON, N.H., March 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and ImmuNext, Inc. today announced a global licensing and research collaboration focused on the study of a preclinical novel target that could lead to potential new medicines for autoimmune...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ImmuNext
Sign Up For FreeTo access detailed company insights
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Novel immunomodulators have been partnered with Janssen, Roche and Sanofi. ImmuNext currently has a clinical stage program with VISTA, a checkpoint regulator, and pre-clinical programs focused on the development of antibodies that target novel immun... Read More
